Changes in Hong Kong stocks | Yinnuo Pharmaceutical-B (02591) plummeted by more than 24% after one year of listing, ushered in the lifting of the ban, the number of unbanned shares was 384 million

The Zhitong Finance App learned that Yinnuo Pharmaceutical-B (02591) plummeted by more than 24%. As of press release, it fell 24.51% to HK$4.99, with a turnover of HK$77,3681 million.

According to the news, Yinnuo Pharmaceutical was listed on the Hong Kong Stock Exchange on August 15, 2025. After one year of listing, the controlling shareholders' and majority shareholders' commitment to ban sales for 12 months expired on August 15. According to data, the number of shares unbanned this time is 384 million shares, accounting for about 91.3% of tradable shares.

According to data from the Hong Kong Stock Exchange, on August 13, Yinnuo Medical experienced a change in positions. The total market value of the inventory was HK$189 million, accounting for 6.32%. The company's shareholders deposited 26.5564 million shares into Haitong International Securities, increasing their shareholding ratio by 6.32%. According to the company's 2025 results, revenue for the period was approximately RMB 131.5 million, mainly from sales of esupaglutide α in China. Net loss was RMB 341 million, up 95.4% year over year.